文献速递肝病

微小RNA-206通过促进胰岛素信号传导和损害脂肪生成来预防肝脂肪变性和高血糖

MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
PubMed 文献 · J Hepatol · 2016-12-23

本研究在高脂饮食诱导的肥胖小鼠和人类肝细胞中探讨微小RNA-206(microRNA-206)缓解肝脂肪变性和高血糖的机制。脂质积累损害了脂肪肝中microRNA-206的生物合成(p<0.01),而递送microRNA-206可产生强大的治疗效应。microRNA-206通过靶向PTPN1促进胰岛素信号并抑制脂肪生成,从而减少脂质和葡萄糖产生。

要点

  • 脂质积累损害肥胖小鼠脂肪肝和人类肝细胞中microRNA-206的生物合成(p<0.01)。
  • 向肥胖小鼠肝脏递送microRNA-206对肝脂肪变性和高血糖产生强大治疗效应。
  • microRNA-206通过靶向PTPN1促进胰岛素信号并抑制Srebp1c转录来减少脂质和葡萄糖产生。

核心结论

  • microRNA-206通过同时促进胰岛素信号传导和损害肝脏脂肪生成,是脂质和葡萄糖产生的有效抑制剂。
  • 研究结果可能为肝脂肪变性和高血糖提供一种新的治疗药物。

研究设计与样本

  • 研究使用高脂饮食诱导的肥胖小鼠和人类肝细胞,通过迷你环载体将microRNA-206递送至小鼠肝脏。

主要发现

  • 脂质积累损害了饮食诱导肥胖小鼠脂肪肝和人类肝细胞中microRNA-206的生物合成(p<0.01)。
  • 向饮食诱导肥胖小鼠肝脏递送microRNA-206对肝脂肪变性和高血糖产生强大治疗效应。
  • microRNA-206与PTPN1的3'非翻译区相互作用并诱导其降解。
  • 通过抑制PTPN1表达,microRNA-206促进INSR磷酸化以促进胰岛素信号,并通过抑制Srebp1c转录损害肝脏脂肪生成。
  • microRNA-206减少人类肝细胞(脂质p=0.006,葡萄糖p=0.018)和饮食诱导肥胖小鼠肝脏(脂质p<0.001,葡萄糖p<0.01)中的脂质和葡萄糖产生。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The paradox of selective hepatic insulin resistance, wherein the insulin-resistant liver fails to suppress glucose production but continues to produce lipids, has been central to the pathophysiology of hepatosteatosis and hyperglycemia. Our study was designed to investigate the mechanism(s) by which microRNA-206 alleviates the pathogenesis of hepatosteatosis and hyperglycemia. METHODS: Dietary obese mice induced by a high fat diet were used to study the role of microRNA-206 in the pathogenesis of hepatosteatosis and hyperglycemia. A mini-circle vector was used to deliver microRNA-206 into the livers of mice. RESULTS: Lipid accumulation impaired biogenesis of microRNA-206 in fatty livers of dietary obese mice and human hepatocytes (p<0.01). Delivery of microRNA-206 into the livers of dietary obese mice resulted in the strong therapeutic effects on hepatosteatosis and hyperglycemia. Mechanistically, miR-206 interacted with the 3' untranslated region of PTPN1 (protein tyrosine phosphatase, non-receptor type 1) and induced its degradation. By inhibiting PTPN1 expression, microRNA-206 facilitated insulin signaling by promoting phosphorylation of INSR (insulin receptor) and impaired hepatic lipogenesis by inhibiting Srebp1c transcription. By simultaneously modulating lipogenesis and insulin signaling, microRNA-206 reduced lipid (p=0.006) and glucose (p=0.018) production in human hepatocytes and livers of dietary obese mice (p<0.001 and p<0.01 respectively). Re-introduction of Ptpn1 into livers offset the inhibitory effects of microRNA-206, indicating that PTPN1 mediates the inhibitory effects of microRNA-206 on both hepatosteatosis and hyperglycemia. CONCLUSIONS: MicroRNA-206 is a potent inhibitor of lipid and glucose production by simultaneously facilitating insulin signaling and impairing hepatic lipogenesis. Our findings potentially provide a novel therapeutic agent for both hepatosteatosis and hyperglycemia. LAY SUMMARY: The epidemic of obesity is causing a sharp rise in the incidence of insulin resistance and its major complications, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). However, there are no effective treatments because the mechanisms underlying both disorders are not well described. We identified microRNA-206 as a novel and effective inhibitor for both glucose and lipid production in liver and potentially provide a unique therapeutic drug for both hepatosteatosis and hyperglycemia.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wu H, Zhang T, Pan F, et al. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis. J Hepatol. 2016. PMID: 28025059. doi:10.1016/j.jhep.2016.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。